Responses
Regular and young investigator award abstracts
Clinical trials in progress
398 AGEN1181, an Fc engineered anti-CTLA-4 antibody, demonstrates clinical activity, alone or in combination with balstilimab (anti-PD-1), and broadens the therapeutic potential of CTLA-4 therapy
Compose a Response to This Article
Other responses
No responses have been published for this article.
